Patents by Inventor Alexis Mikes Kalergis Parra

Alexis Mikes Kalergis Parra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunogenic formulation
    Patent number: 8398993
    Abstract: The present invention describes an immunogenic formulation to be used in mammals against the respiratory syncytial virus (RSV), consisting in the Calmette-Guérin bacillus (BCG) strain or other attenuated Mycobacterium strain that expresses heterologously at least one protein or immunogenic fragment of the RSV subtype A or RSV subtype B strains, originated from proteins NS1, NS2, N, P, M, SH, M2 (ORF1), M2 (ORF2), L, F or G. The genetic material that encodes for these proteins or immunogenic fragments is inserted into the BCG genome or extrachromosomally in one or several copies, which expression is regulated by endogenous or exogenous BCG promoters, either constitutive or inducible. The viral proteins or immunogenic fragments can be expressed by BCG as cytoplasmic-soluble, extracellularly-secreted or cell membrane-bound proteins. The preparation can further contain combinations of previously described formulations. The formulation can be stabilized by freeze-drying (conservation range from 4° C. and 25° C.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: March 19, 2013
    Assignee: Pontificia Universidad Catolica de Chile
    Inventors: Alexis Mikes Kalergis Parra, Pablo Alberto Gonzalez Munoz, Susan Marcela Bueno Ramirez
  • IMMUNOGENIC FORMULATION
    Publication number: 20110200634
    Abstract: The present invention describes an immunogenic formulation to be used in mammals against the respiratory syncytial virus (RSV), consisting in the Calmette-Guérin bacillus (BCG) strain or other attenuated Mycobacterium strain that expresses heterologously at least one protein or immunogenic fragment of the RSV subtype A or RSV subtype B strains, originated from proteins NS1, NS2, N, P, M, SH, M2 (ORF1), M2 (ORF2), L, F or G. The genetic material that encodes for these proteins or immunogenic fragments is inserted into the BCG genome or extrachromosomally in one or several copies, which expression is regulated by endogenous or exogenous BCG promoters, either constitutive or inducible. The viral proteins or immunogenic fragments can be expressed by BCG as cytoplasmic-soluble, extracellularly-secreted or cell membrane-bound proteins. The preparation can further contain combinations of previously described formulations. The formulation can be stabilized by freeze-drying (conservation range from 4° C. and 25° C.
    Type: Application
    Filed: September 17, 2008
    Publication date: August 18, 2011
    Applicant: PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE
    Inventors: Alexis Mikes Kalergis Parra, Pablo Alberto Gonzalez Ez Munoz, Susan Marcela Bueno Ramirez